Histamine dihydrochloride
Ceplene (histamine dihydrochloride) is a small molecule pharmaceutical. Histamine dihydrochloride was first approved as Histamine phosphate on 1982-01-01. It is used to treat allergic rhinitis seasonal and urticaria in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2nd chance mobility pain relief | C200263 | 2024-01-08 |
| activon ultra strength arthritis | OTC monograph not final | 2015-04-22 |
| alo therapeutic massage | C200263 | 2023-11-10 |
| alo therapeutic massage pain relieving | C200263 | 2023-11-10 |
| amino active topical analgesic cream | C200263 | 2023-11-11 |
| arthritis pain relief | C200263 | 2024-12-11 |
| arthritis pain relief cream | OTC monograph not final | 2019-12-09 |
| australian dream back pain | C200263 | 2024-01-18 |
| back pain cream | OTC monograph not final | 2019-12-09 |
| bakers best arthritis pain relief | C200263 | 2023-11-11 |
Show 13 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Histamine dihydrochloride |
| INN | — |
| Description | Histamine dihydrochloride (INN, trade name Ceplene) is a salt of histamine that is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cl.Cl.NCCc1c[nH]cn1 |
Identifiers
| PDB | — |
| CAS-ID | 56-92-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1533310 |
| ChEBI ID | — |
| PubChem CID | 5818 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use